University of Kentucky

UKnowledge
Center for Oral Health Research Faculty
Publications

Oral Health Research

2-27-2008

Application of Prodrugs to Inflammatory Diseases of the Gut
Helieh S. Oz
University of Kentucky, hoz2@email.uky.edu

Jeffrey L. Ebersole
University of Kentucky, jeffrey.ebersole@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/cohr_facpub
Part of the Dentistry Commons, Digestive, Oral, and Skin Physiology Commons, Digestive System
Diseases Commons, and the Pharmaceutics and Drug Design Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
Oz, Helieh S. and Ebersole, Jeffrey L., "Application of Prodrugs to Inflammatory Diseases of the Gut"
(2008). Center for Oral Health Research Faculty Publications. 15.
https://uknowledge.uky.edu/cohr_facpub/15

This Review is brought to you for free and open access by the Oral Health Research at UKnowledge. It has been
accepted for inclusion in Center for Oral Health Research Faculty Publications by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Application of Prodrugs to Inflammatory Diseases of the Gut
Digital Object Identifier (DOI)
https://doi.org/10.3390/molecules13020452

Notes/Citation Information
Published in Molecules, v. 13, issue 2, p. 452-474.
© 2008 by MDPI
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
A correction was published on 1 April 2008: http://www.mdpi.com/1420-3049/13/4/771

This review is available at UKnowledge: https://uknowledge.uky.edu/cohr_facpub/15

Molecules 2008, 13, 452-474

molecules
ISSN 1420-3049
© 2008 by MDPI
www.mdpi.org/molecules
Review

Application of Prodrugs to Inflammatory Diseases of the Gut
Helieh S. Oz* and Jeffrey L. Ebersole
Center for Oral Health Research, College of Dentistry and Department of Internal Medicine,
University of Kentucky, Medical Center, 800 Rose Street, Lexington, KY 40536, USA; E-mail:
jleber2@uky.edu (Jeffrey L. Ebersole)
* Author to whom correspondence should be addressed; E-mails: helieh.oz@uky.edu;
hsoz1@hotmail.com; Phone: +1 (859) 323-0887
Received: 26 January 2008; in revised form: 20 February 2008 / Accepted: 21 February 2008 /
Published: 27 February 2008

Abstract: Oral delivery is the most common and preferred route of drug administration
although the digestive tract exhibits several obstacles to drug delivery including motility
and intraluminal pH profiles. The gut milieu represents the largest mucosal surface
exposed to microorganisms with 1010-12 colony forming bacteria/g of colonic content.
Approximately, one third of fecal dry matter is made of bacteria/ bacterial components.
Indeed, the normal gut microbiota is responsible for healthy digestion of dietary fibers
(polysaccharides) and fermentation of short chain fatty acids such as acetate and butyrate
that provide carbon sources (fuel) for these bacteria. Inflammatory bowel disease (IBD)
results in breakage of the mucosal barrier, an altered microbiota and dysregulated gut
immunity. Prodrugs that are chemically constructed to target colonic release or are
degraded specifically by colonic bacteria, can be useful in the treatment of IBD. This
review describes the progress in digestive tract prodrug design and delivery in light of gut
metabolic activities.
Keywords: Inflammatory bowel disease, Digestive tract, Drug delivery, microbiota,
5-Aminosalicylic acid, Mycophenolate mofetil, Cysteine and Glutathione prodrugs
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Introduction
Oral delivery is the most common and preferred route of drug administration. This is the ideal
route to deliver compounds to colonic sites to treat Inflammatory Bowel Disease (IBD); however; the
digestive tract exhibits several obstacles to drug delivery including gut motility [1-2], stomach and
intraluminal pH profiles, and degradative enzymes [3]. Therefore, prodrugs are designed to transport
intact drug through the stomach and small intestine, but be hydrolyzed by the colonic microbiota to
release the active compound.
The concept of “prodrug” was first introduced by Adrien Albert in 1958 [4] to describe compounds
that undergo biotransformation prior to eliciting their pharmacological effect, i.e. "therapeutic agents
that are inactive but transform into one or more active metabolites." Prodrugs are designed to
overcome pharmaceutical, pharmacokinetic, or pharmacodynamic barriers such as insufficient
chemical stability, poor solubility, unacceptable taste or odor, irritation or pain, insufficient oral
absorption, inadequate blood-brain barrier permeability, marked pre-systemic metabolism, and toxicity
[5]. Furthermore, by attachment of a pro-moiety to the active moiety, a prodrug is formed which is
designed to overcome the barriers that hamper the optimal use of the active principle [6].
The prodrug approach, in which a derivative of the active compound is synthesized, has been
proven to be an effective and important way of overcoming barriers that restrict the application of
many chemical entities as orally administered drugs [7-8]. The colonic drug delivery systems are
mainly based on degradation of a prodrug by microorganisms of the colon flora [9-10] and colonic
enzymes [11-12]. In this review different approaches to colonic drug delivery are discussed.
Inflammatory Bowel Disease
IBD refers to idiopathic inflammatory diseases of the intestine, principally ulcerative colitis and
Crohn’s disease [13]. IBD is characterized by chronic inflammation in the mucosal membrane of the
small and/or large intestine. Although many treatments have been recommended for IBD, they do not
treat the cause but are effective only in reducing the inflammation and accompanying symptoms in up
to 80% of patients. Thus, current medical management of IBD consists of anti-inflammatory and
immunosuppressive agents and biologic drugs, as well as surgery [13-15]. The mortality rate of patients
with Crohn’s disease is 40% greater than those without evidence of disease including Ulcerative
disease [14]. In a retrospective, population based cohort study of mortality by medication use among
IBD included 9032 patients during 1996-2002; with the exception of immunomodulators, the
medications for IBD were not significantly associated with mortality among IBD patients. However,
infections, respiratory diseases and digestive diseases other than IBD have been important specific
cause of death in IBD patients. Despite medical intervention, many patients with IBD suffer from
complications including abscesses, fistulae, intestinal obstruction, chronic blood loss, and intestinal
neoplasia. Also, colorectal cancer is increased in IBD, particularly among male patients [14].
Recent research has lead to the development of several new treatment strategies that target specific
biomolecules. There are multiple therapies in various stages of investigation, including biological agents
such as human recombinant cytokines IL-10 [16], IL-11, IL-12 [17-18] and antisense oligonucleotides to
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intercellular adhesion molecule (ICAM), α4 integrin [19], and monoclonal antibodies to TNF-α [19-20]
and IFN-γ with many more on the horizon. Although these approaches are exciting and represent a move
forward in the treatment of IBD, several issues remain. These include cost, long-term safety, adverse
effects, and the requirement for a parenteral route of administration. Finally, many IBD patients remain
refractory or intolerant to current therapies.
Pathogenesis of IBD
The etiology of IBD remains unknown; however, two primary theories have been proffered focusing
on either a specific persistent infectious agent [21-22] or an abnormal host immune response to
ubiquitous antigens in the luminal constituents. Evidence supports that patients with IBD are genetically
susceptible to this disease, and the defect targets an inability to effectively down-regulate the
inflammatory response to specific antigens or luminal bacteria [23]. Genetically engineered animals
develop spontaneous enterocolitis that resembles IBD [24]. In several of these models (e.g. IL-2-/-, IL10-/- mice, HLA-B27 transgenic rats), the normal resident bacterial microbiota is necessary for the
development of colitis [25-26]. These data suggest that in a genetically susceptible host, a dysregulated
inflammatory/immune response to the nonpathogenic luminal commensal bacteria leads to a chronic
inflammatory process. Inflammatory responses in the intestine can be induced by disorders of
immunoregulation, infectious colitis, impaired circulation, or even toxic compounds.
Striking similarities exist in the clinical and morphologic manifestations among these various forms
of intestinal inflammation. These similarities probably do not reflect directed target cell injury but rather
innocent bystander effects due to the presence of soluble mediators of inflammation [27]. These
mediators include reactive oxygen species (ROS), cytokines, arachidonic acid metabolites, and growth
factors. Cytokines also elicit numerous metabolic responses including altered zinc metabolism [28], and
synthesis of acute phase reactants that also are biochemical/clinical complications of IBD [29]. In
addition, neutrophil and macrophage infiltration suggest the presence of chemotaxins in the mucosal
tissues. Mucosal edema and hyperemia reflect the presence of soluble mediators that induce vascular
permeability and vasodilatation [30].
LPS and TNF production and IBD
The gut milieu represents the largest mucosal surface exposed to microorganisms with 1010-12
colony forming bacteria/g of colonic content. The intestinal micobiota [31] represents 400–500
bacterial species, and encompasses more bacterial cells than eukaryotic cells within the human body
[32]. Approximately, one third of fecal dry matter is made of bacteria/ /bacterial components. Indeed,
the normal gut microbiota is responsible for healthy digestion of dietary fibers (polysaccharides) and
fermentation of short chain fatty acids such as acetate, butyrate and propionate that provide carbon
sources (fuel) for these bacteria, nutrient production, metabolism of dietary carcinogens, and
conversion of prodrugs to active drugs. However, growing evidence suggests that the enteric
microorganisms are critical components in the pathogenesis of IBD and bacterial endotoxemia has
been postulated to play a key role in IBD [23, 32].
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Bacteroides and Clostridium species have been specifically implicated with inflammatory
responses in different animal models of IBD [21,23], whereas other commensals such as Lactobacillus
and Bifidobacterium species, have minimal proinflammatory capabilities and are less likely to
translocate from the lumen to the internal milieu [23]. Lipopolysaccharide (LPS), a cell wall
constituent of Gram-negative bacteria, is present in a high concentration in the normal colonic lumen.
When exposed to LPS, or other stimuli, macrophages release a variety of mediators of inflammation,
of which TNF-α is a prominent component that mediates some disparate effects of LPS challenge [33].
TNF-α is produced earlier than some other cytokines after an LPS challenge and comprises ~2% of the
total secretory products made by activated macrophages [34]. In LPS-treated animals, TNF-α achieves
peak serum concentrations 60-120 minutes after LPS administration. ROS generated during IBD are
also important stimuli for TNF-α production. Administration of purified TNF-α to animals evokes the
same metabolic response as LPS, including fever, anorexia, neutrophilia, and muscle wasting. These
biochemical/clinical complications are also present in IBD [29]. In addition, endotoxemia and elevated
serum concentrations of inflammatory cytokines, including TNF-α, are observed in IBD patients [35].
In these cases, injury is down-regulated by antibody to TNF-α [19-20, 36].
NF-κB and IBD
As a transcriptional activator of genes encoding inflammatory cytokines and adhesion molecules,
NF-κB is an important effector molecule in intestinal inflammation and also a suitable target for antiinflammatory therapy. Mucosal inflammation in clinical IBD has been linked to the upregulated
nuclear translocation of the pro-inflammatory transcription factor complex NF-κB and expression of
pro-inflammatory cytokines, such as TNF-α. Multiple stimuli, including ROS, cytokines and endotoxin,
cause release of IκB and permit NF-κB to enter the nucleus, bind to DNA control elements, and induce
transcription of specific genes (e.g. mediators of inflammation in IBD). These include cytokines (e.g. IL1, 6, 8, 12, and TNF-α), enzymes (e.g. inducible nitric oxide synthase), and cell adhesion molecules (e.g.
E-selectin) [37]. Several established anti-inflammatory and immunosuppressive agents used in the
treatment of IBD are known inhibitors of NF-κB. For instance, glucocorticoids block NF-κB activity in
part by upregulating IκB protein levels [38-39]. Sulfasalazine [40] mesalamine [41] and Cyclosporin A,
all immunosuppressants that target T cells, also inhibit NF-κB [42].
Reactive Oxygen Species (ROS)
Oxidant-mediated injury plays an important role in the pathophysiology of IBD. ROS upregulate
NF-κB and result in further increases in the levels of oxidants and tissue injury in IBD. Inflamed gut
from IBD patients, as well as IBD animal models, are rich in activated macrophages and neutrophils
and these inflammatory cells generate excess amounts of ROS with subsequent increases in oxidative
stress [43]. These ROS include hydroxyl radicals, superoxide anions, hydrogen peroxide, and nitric
oxide. ROS are extremely unstable species due to their high reactivity and may result in lipid
peroxidation and the oxidation of DNA and proteins [44]. The increased generation of highly toxic
ROS exceeds the limited intestinal antioxidant defense system, thereby contributing to intestinal
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oxidative injury in IBD patients [45]. Excessive production of ROS has been demonstrated in
circulating phagocytic and polymorphonuclear leukocytes in IBD patients using a chemiluminescence
assay [46-47] and following stimulation with the bacterial chemotactic peptide N-formyl-methionylleucyl-phenylalanine (fMLP) [48]. Thus, oxidant-mediated injury plays an important role in the
pathophysiology of IBD.
The Prodrug Approach
The primary goal of drug therapy in IBD is to reduce inflammation in the colon that generally
requires frequent intake of high dose anti-inflammatory drugs. Thus, the prodrug approach continues to
provide increased scrutiny as an alternative to this systemic approach. Three classes of Prodrugs,
which target drug to the colon are currently used in IBD or are in experimental stages: (1) Antiinflammatory agents (eg. azu prodrugs, 5-Aminosalicylic acid, amino acids) that can result from
bacteria changing the function of prodrugs or prodrugs treating inflammation which changes the
bacterial ecology; (2) Immunomodulators and Immunosuppressants; and, (3) Antioxidants.
Anti-Inflammatory Prodrugs:
5-Aminosalicylic acid
5-Aminosalicylic acid (5-ASA, 1a, Figure 1) is an effective compound to attenuate the
inflammatory response in IBD while its mechanism of action is not fully understood. Thus, it usually
fails to reach the colon leading to significant adverse effects such as ulcerogenic potential [49].
Therefore, a prodrug approach for colonic delivery of 5-ASA has become a rational system of drug
delivery for the topical treatment of IBD. 5-ASA triggers the peroxisome proliferator-activated
receptor (PPAR-γ) family of nuclear receptors, which regulate inflammation, cell proliferation,
apoptosis, and metabolic function. PPAR-γ receptors are highly expressed in colonic epithelia and their
expression is upregulated by the gut bacteria [50].
Figure 1. (1a) Molecular structure of 5-Aminosalicylic acid (5-ASA); (1b) Molecular
structure of Sulfasalazine (5-ASA linked to Sulfapyridine by the azo bond).
COOH
OH
H2N
1a: 5-ASA
HOOC
HO

N N

SO2 N
N

1b: Sulfasalazine
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In order to achieve an effective colonic delivery, a drug needs to be protected from absorption
and/or the environment of upper GI tract and then rapidly released into the proximal colon, which is
the optimalsite for colon-targeted delivery of the drug. Colonic drug delivery through colon-specific
prodrug activation may be accomplished by the utilization of the high activity of certain enzymes at
the target site relative to non-target tissues, enabling for prodrug conversion to active drug [51].
The microbiota of the GI tract consists of a coexisting mixture of aerobic, facultative anaerobic,
and strict anaerobic bacteria in a complex ecosystem. These bacteria produce a wide range of enzymes,
such as β-glucuronidase, β-xylosidase, α-arabinosidase, β-galactosidase, nitroreductase, azoreductase,
deaminase, urea hydroxylase, etc [52]. The reductive environment of the bacterial microbiota can be
utilized for colon targeting. The prodrug approach has been successfully utilized with sulfasalazine
(an azo prodrug 5-ASA and sulfapyridine, 1b, Figure 1) for targeting drugs to the colon [51]. The azo
prodrugs are poorly absorbed in the stomach and small intestine. The azo linkage is cleaved by the
azoreductases released by the colonic anaerobic bacteria to form a pair of amines [53]. The majority
of side effects of sulfasalazine, eg. hepatotoxicity, hypospermia, and severe blood disorders, are due to
sulfapyridine. Even though different prodrugs of 5-ASA like balsalazide, ipsalazine and olsalazine [911] have been reported, few of them have extended beyond the stage of clinical trials.
Balsalazide, a prodrug of 5-ASA and an analogue of sulfasalazine, is linked to the carrier 4aminobenoyl β-alanine via an azo-bond and is specifically converted to 5-ASA by azo-reducing
bacteria present in the colon [54]. The prodrug remains intact in the gastrointestinal tract until it
reaches the colon. This agent uses a mode of drug administration to exert a local anti-inflammatory
effect directly on the inflamed lining of the intestinal wall. Alternatively to colon targeting, many
prodrug projects are directed toward avoiding gastrointestinal side effects. Olsalazine is a dimer of 5ASA linked by an azo-bond to avoid the sulfapyridine moiety [9-11]. The slow release 5-ASA
preparations (enteric-coated; eg. mesalamine, Pentasa, Asacol) have been approved by the FDA.
Pentasa microgranules are coated with a semipermeable membrane of ethylcellulose with amphoionic
properties. 5-ASA is slowly released over time from the granules into the intestine, and enhanced with
pH above 6.0. [55]. However, the need for a safer, colonic delivery of prodrugs of 5-ASA with
nontoxic carriers and non- ulcerogenic potential still remains.
Still in an exploratory stage, recently an amino acid (mutual) azo prodrug of 5-ASA was
synthesized by coupling L-tryptophan with salicylic acid, for targeted drug delivery to the inflamed
colonic tissue in IBD [56]. The structure of the synthesized prodrug was confirmed by elemental
analysis, IR and NMR spectroscopy. In vitro kinetic studies showed negligible release of 5-ASA in
HCl buffer (pH 1.2), whereas 18% was released in phosphate buffer (pH 7.4) over a period of 7 h. In
rat fecal matter, 87.9% of 5-ASA was released with a half-life of 143.6 min, following first order
kinetics. The azo conjugate was evaluated for its ulcerogenic potential by Rainsford's cold stress
method. The ameliorating effect of the azo conjugate and therapeutic efficacy of the carrier system was
evaluated in TNBS-induced experimental colitis model. The synthesized prodrug was found to be
equally effective in attenuating the colitis in rats as that of sulfasalazine without the ulcerogenicity of
5-aminosalicylic acid.
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Acid-regulation and short chain fatty acids
The proton pump inhibitor omeprazole utilizes the acidic environment of the stomach [57-58].
Omeprazole is a prodrug of a sulfonamide that exerts its potent ant-iulcer effects by covalently
modifying cysteine residues on the luminal side of the proton pump (i.e., H+/K+-ATPase) in the
oxyntic mucosa of the stomach. This prodrug only exerts its anti-secretory effect in the acidic
environment of the oxyntic mucosa of the stomach.
Short chain fatty acids
Short chain fatty acids (SCFA), mainly acetate, propionate and butyrate, are produced in the
colonic environment by action of bacterial fermentation to maintain the normal physiological function
of the gut. The effects of SCFA include modulation of colonic muscular activity, stimulation of
electrolyte and fluid uptake and enhancement of blood flow [59-60]. Of the major SCFA, butyrate
appears to be a preferred oxidative substrate for colonocytes. It also acts to maintain a normal
phenotype in these cells through repair of damage to DNA and inhibition of apoptosis in normal cells
and its promotion in colon tumor cells in vitro [59-61] and in vivo rat treated with carcinogen
azoxymethane [62]. IBD results in SCFA deficiency [63]. SCFA consumed directly in foods or
beverages are rapidly absorbed in the fore-gut and fail to reach the colon [64]. However, acylated
maize starch with butyric anhydride was shown to produce resistant starch that increased SCFA in the
rat gut, apparently through bacterial release of the esterified fatty acid and fermentation of the residual
starch [65].
Carnitine (β-hydroxy-γ-trimethylaminobutyrate)
Carnitine (β-hydroxy-γ-trimethylaminobutyrate) is obligatory for transport of long-chain fatty acids
into mitochondria for subsequent β-oxidation [66]; it plays a critical role in energy metabolism of the
tissues that derive a substantial portion of their metabolic energy from fatty acid oxidation such as
heart, skeletal muscle, liver [67-68]. Butyrate, a bacterial fermentation product, is beneficial for
prevention/treatment of ulcerative colitis. Butyryl-L-carnitine, a butyrate ester of carnitine, may have
potential for treatment of IBD since butyryl-L-carnitine would supply both butyrate and carnitine. LCarnitine is absorbed in the intestinal tract via the carnitine transporter OCTN2 and the amino acid
transporter ATB. Loss-of-function mutations in OCTN2 may be associated with IBD, suggesting a role
for carnitine in intestinal/colonic health. In contrast, ATB is upregulated in bowel inflammation [69]
Immunomodulators and Immunosuppressors
Mycophenolate mofetil
Mycophenolate mofetil (MMF, Figure 2) is an ester prodrug of mycophenolic acid, the active
moiety that gives the drug its immunosuppressive properties [70]. A century ago (1896), Gosio [71]
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isolated mycophenolic acid from a culture Penicillium species and noted its antibacterial properties.
Mycophenolic acid decreases de novo synthesis of guanosine nucleotides by reversible inhibition of
inosine monophosphate dehydrogenase (IMPDH) [72]. This prodrug acts against T and B
lymphocytes, because these cells depend on the de novo synthesis of purines for proliferation, whereas
other cell types, such as neutrophils and macrophages, can use salvage pathways [69]. Mycophenolate
mofetil is unique because of its dual activity as an immunosuppressant, as well as an antimicrobial
with a novel action against Pneumocystis carinii pneumonitis [73-75]. Mycophenolic acid is known
to inhibit growth of intestinal smooth muscle and synthesis of fibronectin [76], and may be useful to
inhibit smooth-muscle hyperplasia and stricture formation in Crohn’s patients.
Figure 2. Molecular structure of the immunomodulator mycophenolate mofetil (MMF).
O

CH3
O

O
O

N
O

Mycophenolate mofetil
A number of clinical trials [77-80] have suggested a therapeutic role for MMF in patients with
ulcerative colitis and Crohn’s disease. These controlled trials have shown efficacy of MMF in patients
with active IBD. Based on these trials, patients with IBD refractory to other IBD therapies
(corticosteroids, azathioprine or 6-mercaptopurine, methotrexate, and infliximab, monoclonal antibody
against TNFα) may be treated with MMF in selected circumstance [83]. The development of colitis in
patients treated with MMF has been described in four renal-transplant recipients [81]. However, these
patients were receiving high-dose MMF. The development of colitis in these patients may be caused
by enterohepatic cycling of mycophenolic acid resulting in high colonic concentrations of the
metabolite [82].
Azathioprine
Azathioprine, a thiopurine prodrug, is another immunosuppressant used in IBD and liver
transplantation patients [77-78,80,84]. Approximately 1 in 10 patients suffers side effects in response
to the drug, such as bone marrow toxicity [84]. There is evidence that polymorphisms in the genes
encoding thiopurine methyltransferase and inosine triphosphate pyrophosphatase predict adverse drug
reactions to Azathioprine therapy. Furthermore, common genetic polymorphisms in the gene encoding
methylenetetrahydrofolate reductase may have an indirect impact on thiopurine drug methylation by
influencing levels of the methyl donor S-adenosylmethionine.
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Glucocorticosteroids
Corticosteroids are commonly prescribed for treatment of moderate to severe IBD however,
numerous adverse effects limit their long term use [79]. Budesonide is a nonhalogenated corticosteroid
with a high affinity for the glucocorticoid receptor. Budesonide is a 1:1 mixture of the epimers
(22R+22S), which both are rapidly eliminated with a terminal half-life of 2.7±0.6 h [85]. Budesonide is
extensively metabolized by hydroxylation, while the cytochrome P450 isoenzyme CYP3A4, expressed
in high amounts in hepatocytes and epithelial cells of the intestinal wall, is the main responsible
isoenzyme for its rapid elimination. “Budenofalk®” is a slow releasing Budesonide composed of a hard
gelatin capsule and acid-resistant pellets. The pellets are covered with Eudragit, with a delayed release
at pH > 6.4. Following ingestion of the capsules more budesonide is available in the region of the
terminal ileum. [85]. Budesonide-β-D-glucuronide another prodrug is hydrolyzed by colonic bacterial
and mucosal beta-glucuronidase to librate free budesonide into the colonic milieu. Hydrolysis rates of
budesonide-β-D-glucuronide in fecal specimens from IBD patients and normal volunteers are similar.
pH reduction in the colon of IBD patients may inhibit the bacterial hydrolysis of this prodrug.
Antioxidants
Antioxidant status has been described to be compromised in the intestinal mucosa from patients
with IBD [46-47,86-87]. In vitro studies using enterocytes have also demonstrated the damaging
effects of exposure to oxidants [88]. Similar studies reveal that the colons of IBD patients produce
more oxygen free radicals compared with those of control subjects [57,48]. In addition, using a
chemiluminescence assay, significantly elevated levels of reactive oxygen metabolites were found in
the actively inflamed mucosa of IBD patients [47,89]. Colitis animals showed an increase in plasmaoxidized proteins, indicating that DSS induced oxidative stress to be at the systemic level that persisted
until the end of the treatment [90-94]. Oxidative stress is linked with the stimulation of the immune
system [18].
Glutathione (GSH)
The endogenous tripeptide glutathione (GSH), is the most important intracellular defense agent in
mammalian organs, including the gut. GSH is involved in protein folding and protein synthesis, as well
as in intracellular signaling [90]. Glutathione is the most abundant cellular antioxidant synthesized by
animal cells. GSH plays an essential role in cell biology and modulates cell responses to redox changes
associated with the presence of ROS. GSH neutralizes free radicals and ROS toxicity and is essential
for both the functional and structural integrity of the gut. GSH may be depleted during inflammatory
illness such as IBD [92, 94] and acetaminophen toxicity [95-97] and this GSH deficiency predisposes
animals to organ failure and death after an otherwise nonlethal period of hypotension [89, 98]. Indeed
GSH-deficient mice show severe degradation of the jejunum and colonic mucosa and have body
weight loss and diarrhea [89]. Depletion of GSH induced enlarged lymphoid aggregates in the intestine
by recruitment of lymphocytes from the peripheral circulation [99]. The depletion in tissue levels of
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GSH has been implicated as a component of the inflammatory complications. Supplementation with
GSH monoethylester has been reported to prevent these lymphoid aggregates [100]. Data showed a
significant decrease in the blood as well as intestinal tissue levels of GSH in the DSS-induced colitis
model [94]. GSH plays an essential role in cell biology and modulates cell responses to redox changes
associated with the presence of ROS. In vivo studies indicated that oxidized colonic mucosal redox
status stimulated colonic mucosal growth in rats. The data supported that GSH is required to maintain
normal colonic and plasma cysteine/cystine homeostasis [100]. Because GSH deficiency is associated
with severe injury such as inflammation and sepsis, treatment strategies that maintain GSH levels may
decrease the incidence of organ failure. One strategy for preventing this injury is to boost the levels of
GSH within the cells. However, GSH is not taken up directly by most cell phenotypes and must first be
broken down into its component amino acids (cysteine, glutamate, and glycine) by enzymes including
δ-glutamyltranspeptidase.
Cysteine Prodrugs:
Cysteine an extracellular reducing agent, is a critical substrate for protein synthesis, and the ratelimiting precursor to GSH [101]. In vivo studies indicated that oxidized colonic mucosal redox status
stimulated colonic mucosal growth in rats. Therefore, data suggested that GSH is required to maintain
normal colonic and plasma cysteine /cystine homeostasis. Cysteine can be given orally to increase
GSH [102] or to chelate trace elements in the gut, thereby decreasing absorption of both cysteine and
the trace element [103].
Cysteine (CYSH) + Glutamate (GLU) = δ-glutamylcysteine (G-CLU-CYSH)
G-GLU-CYSH + Glycine (GLY) = GSH
2GSH + H2O2 = GSSG + 2H2O
GSSG + NADPH = 2GSH + NADP

Cysteine and glutathione prodrugs
Administration of N-acetylcysteine (NAC), a cysteine prodrug, in a rat model of chemically
induced colitis (TNBS) attenuated acute colitis through increased mucosal GSH levels [104],
suggesting that cysteine prodrugs may be beneficial in the acute relapse of IBD. Dextran sodium
sulfate (DSS) treatment of mice mimics IBD in that it provokes inflammation and macrophage
activation, with subsequent loss of epithelial integrity, and increases luminal Gram-negative
microbiota [105]. Rebamipide, a drug that inhibits the production of free radicals, was shown to act as
an anti-inflammatory agent in chronic DSS-induced colitis [106].
We investigated the efficacy of three different cysteine prodrugs against colitis in DDS-induced
murine model. 2(RS)-n-Propylthiazolidine-4(R)-carboxylic acid (PTCA), is an L-cysteine prodrug that
stimulate GSH biosynthesis with a masked sulfhydryl group in the form of a thiazolidine-4-carboxylic
acid to stabilize it against oxidation (Figure 3a) [107]. PTCA undergoes ‘demand–pull’ hydrolysis and
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release GSH about 20% more efficiently than NAC [108]. 2(RS)-D-ribo-(1’,2’,3’,4’-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid, (RibCys) is another L-cysteine prodrug (D-Ribose-Lcysteine), that like PTCA, can liberate the sulfhydryl-containing amino acid L-cysteine in vivo by nonenzymatic, hydrolytic dissociation (Figure 3b) [100]. The ester of the carboxylic acid (carrier-linked
prodrugs) is cleaved by hydrolysis (enzymatic and/or chemical) to liberate the active compound.
Figure 3. Molecular structures of three cysteine and glutathione prodrugs: a) 2(RS)-nPropylthiazolidine-4(R)-carboxylic acid (PTCA), an L-cysteine prodrug; b) 2(RS)-D-ribo(1’,2’,3’,4’-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) D-Ribose-Lcysteine and c) L-cysteine-glutathione mixed sulfide (CySSG).
S
CH2CH2CH3

PCTA

N
H

HO

OH

COOH

S

RibCys
OH OH N
H

S S
H2N

COOH

H
N

COOH
CySSG

COOH HN
O

COOH
NH2

L-cysteine-glutathione mixed sulfide (CySSG) is a ubiquitous GSH derivative present in
mammalian cells and has been suggested to be a depot form of GSH [109]. CySSG, a glutathione
delivery agent [110] can liberate both GSH and L-cysteine by a glutathione reductase-catalyzed
reaction with GSH (Figure 3c) [111].
We have shown that DSS-treated mice develop severe colitis, with decreased GSH concentrations
in blood, colonic tissue and colon and liver when compared to normal controls [92,94,112]. In
addition, DSS-treated animals had decreased hematocrits, and elevated inflammatory markers such as
enzyme Cyclooxygenase (Cox-2), CD68, acute protein serum Amyloid A (SAA), and inflammatory
cytokines (IL-6, IL-12, TNF-α) including osteopontin (OPN).
OPN is an important pro-inflammatory glycoprotein secreted by various cell types such as
macrophages and intestinal epithelial cells [113]. In this study, PTCA-treated mice had significantly
improved colonic lesions, with higher levels of blood and hepatic GSH, and lower GSSG
concentrations compared to untreated DSS animals [114]. Based on our findings these antioxidant
prodrugs reduced disease activity in the colitis. Oral administration of PTCA has been shown to
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protect against acetaminophen (APAP)-induced hepatic damage and necrosis, as well as GSH and
cysteine depletion [92,115].
Figure 4. Relative densities of representative western blot analyses (n= 3) indicating
significant upregulation of Cyclooxygenase (Cox-2) protein expression in colonic tissue
from colitis mice (DSS) which is normalized with prodrug therapy especially in PTCA
animals. (DSS)- Represents colitis provided with DSS- supplemented water. PTCA,
RibCys and CYSSG represent those mice provided with DSS- containing water and
treated with one of cysteine/GSH prodrugs. (Courtesy of Oz et al, Translational Research
2007).

Figure 5. Hepatic concentration of reduced GSH, the major source of gut antioxidant,
was depleted in colitis animals (DSS) and normalized with prodrug therapy. (GSH was
measured by HPLC).
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The results demonstrated a high degree of tissue selectivity in the APAP-induced depletion of GSH
and cysteine concentrations, and in the effectiveness of PTCA in maintaining and even elevating
sulfhydryl levels in extrahepatic tissues of APAP-treated mice [116], while the protective effect of
PTCA was related to prevention of hepatic sulfhydryl depletion. Similarly, oral administration of
PTCA provided protection against steatohepatitis by attenuating the expression of deleterious proinflammatory and fibrogenic genes in a dietary rat model [117]. Other studies showed that PTCA
significantly increased GSH biosynthesis in cultured rat lens compared to untreated controls [118], and
prevented naphthalene-induced experimental cataracts in mice [108]. Thus, our studies indicate that
PTCA, RibCys and, to a lesser extent, CySSG, provide protection against colitis in this murine model.
These data also reinforce our previous report describing the novel protective action of PTCA against
different inflammatory complications including IBD [92,114,117].
S-adenosylmethionine (SAMe, Adomet) Metabolism and Gut
SAMe, an antioxidant and a GSH precursor is an obligatory intermediate in normal cell physiology
and in the transsulfuration pathway. SAMe serves as an antioxidant not only because of its role as a
precursor for GSH biosynthesis, but also because of its capacity to interact directly with ROS. The
conversion of methionine to SAMe involves transfer of the adenosyl moiety of ATP to the sulfur atom
of methionine [119]. This process is catalyzed by methionine adenosyltransferase (MAT) in cells
[120]. The MAT gene is considered one of 33 genes required for survival and MAT is highly
susceptible to oxidative stress [119]. Besides being a precursor for syntheses of polyamines, choline,
and GSH, SAMe is also the major biologic methylating agent for DNA, RNA, phospholipids, biologic
amines, and proteins. SAMe is required for the metabolism of nucleic acids, and for the maintenance
of the structure and function of membranes [121]. SAMe in stable enteric capsule (cellulose gel)
synthesized in the form of disulfate tosylate salt and, methacrylic acid copolymer has been shown to
provide intestinal specific drug delivery systems with pH sensitive swelling and drug release
properties. Methacrylic-type polymeric prodrugs have been shown to have a defined bioavailability.
Ulcerative colitis is associated with a selective reduction of n-butyrate oxidation by colonic
epithelial cells [122, 123]. The reasons for this are not completely understood. Bacterial production of
anionic sulfide is reported to be increased in the colon of IBD patients and these sulfides can cause
metabolic damage to colonocytes [123]. Incubation of colonic cell suspensions with sulfide induced a
significant inhibition of 14CO2 production as compared with controls. Sulfide toxicity in isolated
colonocytes can be reversed by methyl donors. The addition of S-adenosylmethionine-1,4-butane
disulfonate to the cell suspension reversed this effect in proximal but not in distal cell incubations,
suggesting a greater susceptibility of the distal colon to the sulfide effect [124].
The role of mucosal detoxification of sulfide by thiolmethyltransferase (TMT)-mediated
methylation was suggested as crucial in protecting the healthy colonic mucosa from the adverse effects
of luminal sulfide. In the human colon, methylation appears to protect colonic epithelial cells against
sulfide-induced inhibition of n-butyrate oxidation. Luminal anionic sulfide may contribute to epithelial
damage in ulcerative colitis [125]. Erythrocyte TMT activity was elevated in patients after
proctocolectomy for Crohn's disease and Ulcerative Colitis. In patients with active stage of ulcerative
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colitis, the mucosal spermidine concentration was increased due to exogenous uptake in comparison
with patients in remission or in healthy controls. The activities of ornithine decarboxylase and Sadenosylmethionine decarboxylase, rate-limiting enzymes of polyamine biosynthesis, were lower in
the patients with ulcerative colitis [125]. These findings in patients suggest that sulfide detoxification
may be important in the pathogenesis of IBD. Recent investigations show a close interaction between
endogenous SAMe concentrations (measured by HPLC) and cytokine production in animal models
[92, 97, 114, 117, 126]. SAMe deficiency increased TNFα production and tissue injury while
exogenous SAMe supplementation decreased TNFα production in these animals. SAMe
supplementation significantly improved blood level of GSH, and serum SAA level, as well as pathological scores
in colitis [92] suggesting a therapeutic value in treatment of IBD. Oral administration of SAMe protected
against acetaminophen hepatotoxicity in mice [97]. In addition, we reported a therapeutic effect of
SAMe in oral form against liver injury, elevated liver enzymes aspartate transaminase and alanine
transaminase and over expression of inflammatory and fibrotic genes (e.g. IL-1β, IL-6,TNFα, MMP39) in a dietary rat model for Nonalcoholic Steatohepatitis (NASH) [117, 126]. We postulate that SAMe
may also prove to be useful dietary supplement in the treatment of inflammatory disease in patients.
Figure 6. Liver enzymes (ALT and AST) are significantly increased in rats on methionine
Choline deficient diet (MCD) compared to those fed methionine choline sufficient diet
(MCS). In contrast, SAMe and PTCA therapy normalize these deleterious enzyme
activities in rats on an MCD diet (Model for steatohepatitis (NASH).
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Conclusions
Oral delivery is the most common and preferred route of drug administration although the digestive
tract exhibits several obstacles to drug delivery including motility and intraluminal pH profiles.
Currently there is no cure for IBD. Although many treatments have been recommended for IBD, they
do not treat the cause but are effective only in reducing the inflammation and accompanying symptoms
[13-20, 49, 52, 85]. Thus, current medical management of IBD consists of anti-inflammatory,
immunosuppressive agents and other biologics. Since IBD patients undergo prolonged periods of
treatment, prodrugs are considered as the most practical approach for targeting drugs to the colon in
IBD patients. Three classes of prodrugs proven effective in IBD include: (1) anti-inflammatory agents
(e.g. 5-ASA, azo prodrugs, amino acids) that can result from bacteria changing the function of
prodrugs or prodrugs treating inflammation which changes the bacteria ecology; (2)
immunomodulators and immunosuppressants; and (3) antioxidants. Improved drug delivery systems
are required for drugs currently in use to treat localized diseases of the colon. Therefore, using IBD
prodrug modalities to target specifically colonic tissue may lower the drug dosage, supply the drug
only where required by maintaining the drug in its intact form close to the target site, and finally,
reduce the incidence of systemic side effects in these patients.
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